J&J reports durability data for bladder cancer 'pretzel' drug
Johnson & Johnson said its drug-device combo for bladder cancer achieved a high rate of complete responses lasting at least a year, according to the latest data cut from a registrational trial. Almost 45% of ...
Johnson & Johnson said its drug-device combo for bladder cancer achieved a high rate of complete responses lasting at least a year, according to the latest data cut from a registrational trial.
Almost 45% of ...
